Listed BioTech firm Silence Therapeutics has appointed Craig Tooman as the its Chief Financial Officer (CFO) and member of the Executive Leadership Team.
The London firm deals in the discovery, development and delivery of novel therapeutics for the treatment of diseases with significant unmet medical need.
Tooman brings to the firm a successful career in the biopharmaceutical industry spanning more than 30 years, including 15 years of experience as a public company CFO.
Most recently, he was CFO and COO at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco.
Before Aratana, Tooman was the CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau, and currently serves on the Supervisory Board and Audit Committee of CureVac, which accomplished a highly successful IPO on Nasdaq in August of 2020.
Mark Rothera, President and CEO of Silence Therapeutics said the appointment would help to build its U.S. footprint.
“Craig brings a deep understanding of financial strategy, U.S. capital markets and business development to Silence,” he said.
“We are delighted to have him join Silence’s Executive Leadership Team. His appointment comes at a time of significant opportunity and growth, highlighted by the advancement of our two wholly owned product candidates into the clinic and three anticipated clinical data readouts this year. “
Tooman added: “Silence is a fast-growing company with ground-breaking technology that stands out in the RNAi space. It is exciting to join at this stage of the Company’s journey, following a number of recent successful partnerships and transformational deals. I look forward to working with the team to continue the momentum.”